Teva Barred From Agreeing ‘No-Authorized Generics’ Deals Under Reverse-Payment FTC Settlement
Modifying terms to a 2015 consent decree involving its Cephalon unit, Teva has reached a global settlement agreement with the US Federal Trade Commission that dismisses Teva and its affiliates from three outstanding antitrust cases.
You may also be interested in...
Agreeing a deal that it would not face an authorized generic during its 180-day market exclusivity for generic Opana ER contributed to Amneal's Impax striking an illegal pay-for-delay settlement, the FTC is alleging
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
Three ANDA sponsors – HEC’s Sunshine Lake, Sigmapharm and Unichem – for generic versions of Eliquis had elected to take their Hatch-Waxman case to trial but were soundly beaten by originator’s Bristol-Myers Squibb and Pfizer. A launch in 2031 could now be their best, and only, option.